Narrative review examines Vagus nerve stimulation mechanisms and biomarkers in drug-resistant epilepsy

This publication is a narrative review summarizing existing evidence rather than a primary trial. The scope focuses on patients with drug-resistant epilepsy receiving Vagus nerve stimulation as an intervention or exposure. The authors do not report specific sample sizes, follow-up durations, or adverse event rates within this synthesis. Consequently, quantitative conclusions regarding efficacy or safety cannot be drawn from this specific source alone.

Experimental and clinical evidence indicates that therapeutic effects involve distributed brain networks and multiple neurochemical pathways. The review outlines how machine learning approaches and adaptive closed-loop neuromodulation strategies may support the development of clinically useful VNS biomarkers. These concepts represent potential directions for future research rather than established clinical protocols for immediate implementation.

Limitations acknowledged by the authors include methodological challenges in the analysis of periodic and aperiodic EEG components. Safety data such as adverse events, serious adverse events, and discontinuations are not reported in this source. The certainty of the evidence is not reported, requiring careful interpretation of the synthesized arguments regarding neural mechanisms.

Clinicians should recognize that this narrative review provides context rather than definitive trial outcomes. Practice relevance centers on understanding potential biomarker development through advanced neuromodulation strategies. The source explicitly notes it is a narrative review summarizing existing evidence, not a primary trial. Understanding these boundaries helps manage expectations regarding the strength of the recommendations provided.